2009
DOI: 10.1159/000254389
|View full text |Cite
|
Sign up to set email alerts
|

Questions about Chemokine and Chemokine Receptor Antagonism in Renal Inflammation

Abstract: Chemokines remain attractive therapeutic targets for modulating inflammatory diseases in all areas of medicine including acute and chronic kidney disease. Industry has launched huge programs for the development of chemokine antagonists, and clinical trials with chemokine and chemokine receptor antagonists are ongoing. However, chemokine biology remains an area of unexpected discoveries. Here we discuss a number of questions which need to be addressed to further explore the potential of chemokine antagonism in … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
14
0

Year Published

2010
2010
2016
2016

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 10 publications
(14 citation statements)
references
References 39 publications
0
14
0
Order By: Relevance
“…Although interference with chemokine action holds great promises for the treatment of inflammatory renal diseases in experimental models, the chemotactic actions of chemokines in both initiation and progression of kidney diseases are much more promiscuous and complicated than we thought. 1,2 Thus, much effort is required to further understand the mechanisms of chemokine function to develop innovative antichemokine therapies for human renal disease. …”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Although interference with chemokine action holds great promises for the treatment of inflammatory renal diseases in experimental models, the chemotactic actions of chemokines in both initiation and progression of kidney diseases are much more promiscuous and complicated than we thought. 1,2 Thus, much effort is required to further understand the mechanisms of chemokine function to develop innovative antichemokine therapies for human renal disease. …”
Section: Resultsmentioning
confidence: 99%
“…As several recent reviews have dealt with the basic biology, mouse models, and blockade studies of chemokines in renal diseases, [1][2][3][4][5][6][7][8][9][10][11] we focus here on recent developments in pathophysiology of that chemokine effect. …”
mentioning
confidence: 99%
“…19 In recent years, growing evidence regarding their roles in inflammation, chemokines and their receptors have been proposed to be regarded as attractive therapeutic targets for treatment of inflammatory renal diseases such as glomerulonephritis. 19,20 Indeed, in vivo treatment with an IL-8-blocking antibody reduced glomerular neutrophil accumulation and proteinuria in an acute immune complex glomerulonephritis in rabbits. 21 CXCR1, a receptor of IL-8, has been shown to be expressed on podocytes in vitro and in vivo during membranous glomerulonephritis, 22 as well as on neutrophils in membranoproliferative glomerulonephritis, lupus nephritis, and crescentic glomerulonephritis.…”
Section: 18mentioning
confidence: 99%
“…These studies have produced some surprises. For example, P-selectin deficiency [49,55], Mac-1 deficiency [40] or chemokine blockade [56] paradoxically adversely affect glomerular inflammation. These unexpected results are explained by different processes.…”
Section: Mobilization Of Foot Soldiersmentioning
confidence: 99%